Trends in Antiparkinsonian Medication Use in New Zealand: 1995–2011
Figure 3
Actual and projected changes in antiparkinsonian agent consumption: 2005–2011. Projected values calculated using the yearly percentage change in the number of people receiving prescriptions for each drug group. (a) Levodopa (L-dopa), (b) catechol-o-methyl transferase inhibitors (COMTI), (c) amantadine, (d) dopamine agonists, (e) selegiline, and (f) anticholinergics.
